Yuying Wang

Yuying Wang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2026 in Environmental Research
Verified
Journal Article
Closed access
YJYufeng Jia
Yufeng Jia
CWChenyu Wang
Chenyu Wang
YTYonghong Tao
Yonghong Tao
YWYuying Wang
Yuying Wang
LYLianzheng Yu
Lianzheng Yu
GLGuangcong Liu
Guangcong Liu

12 March 2026 in Biological Research
Verified
Journal Article
Open access
PDF file
SWShuo Wu
Shuo Wu
YSYuexuan Su
Yuexuan Su
RZRuishan Zhang
Ruishan Zhang
YWYuying Wang
Yuying Wang
XLXiang Li
Xiang Li
Background: Metabolic alterations are key factors driving the development of breast cancer. Among them, metabolic reprogramming is an important biological hallmark of breast cancer. It is crucial to gain in-depth understanding of the relevant mechanisms and find effective treatment strategies. Isoimperatorin (ISO), a natural furanocoumarin, exhibits various pharmacological effects such as anti-inflammatory and antiviral activities. However, the impact of ISO on the growth of breast cancer cells and its underlying mechanisms remain unclear. Methods: Cell culture, transfection, and animal experiments were employed. CCK -8, colony formation, and flow cytometry were used to detect cell proliferation, apoptosis, and ROS levels. miRNA-Seq, qRT-PCR, and Western Blotting were applied to analyze gene and protein expression. Results: ISO inhibited breast cancer cell proliferation, induced apoptosis and ROS accumulation, and suppressed the Warburg effect. ISO upregulated miR- 874-3p, which directly targeted the 3′-UTR of POU2F1, inhibiting the transcriptional activation of key glycolytic genes. Blocking this axis reversed ISO’s tumor-suppressive effects in vitro and in vivo. Conclusion: This study first reveals a novel mechanism by which ISO regulates breast cancer metabolism and apoptosis via the miR-874-3p/POU2F1 axis, highlighting ISO’s potential as a dual metabolic-redox intervention agent and providing a new combined therapeutic target for breast cancer.